Nasdaq · CIK 0001321834
QCLS Q/C TECHNOLOGIES, INC.
Insider trading from SEC Form 4. Last filing 11 d ago.
In brief
Q/C TECHNOLOGIES, INC. (QCLS) has 25 SEC Form 4 filings on file from 9 insiders, the latest filed on Oct 2, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
1 open-market trade has been scored at QCLS. The newest: Chelsea Sierra Voss (director) bought $5,522 of stock on Mar 30, 2026, filed May 14, 2026, scored 15 (weak).
Last 90 days
Signals
Open-market buys and sells at Q/C TECHNOLOGIES, INC., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | Chelsea Sierra Voss director buy | $5,522 1,753 shares | +3% | - |
Transactions
Every row filed, 31 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 10, 2026 | Joshua Silverman Executive Chairman | AGrant or award Common Stock | +16,620 | $0.00 | $0 | 133,455 | 11 d ago |
| Apr 13, 2026 | Joshua Silverman Executive Chairman | AGrant or award Common Stock | +16,806 | $0.00 | $0 | 116,835 | 11 d ago |
| Apr 13, 2026 | Joshua Silverman Executive Chairman | AGrant or award Employee Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | 11 d ago |
| Oct 1, 2026 | Joshua Silverman Executive Chairman | AGrant or award Common Stock | +77,390 | $0.00 | $0 | 210,845 | 11 d ago |
| Mar 30, 2026 | Chelsea Sierra Voss director | POpen-market purchase Common stockindirect: By Roth IRA | +1,753 | $3.15 | $5,522 | 61,555 | May 14, 2026 |
| Apr 13, 2026 | Billy Joe White director | AGrant or award Employee Stock Option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Apr 15, 2026 |
| Apr 13, 2026 | Chelsea Sierra Voss director | AGrant or award Employee Stock Option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Apr 15, 2026 |
| Apr 13, 2026 | Joshua Silverman Executive Chairman | AGrant or award Common stock | +162,162 | $0.00 | $0 | 262,191 | Apr 15, 2026 |
| Apr 13, 2026 | Mitchell Glass Chief Medical Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Apr 15, 2026 |
| Apr 13, 2026 | Stephen Friscia director | AGrant or award Employee Stock Option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Apr 15, 2026 |
| Apr 13, 2026 | Bruce Bernstein director | AGrant or award Employee Stock Option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Apr 15, 2026 |
| Apr 13, 2026 | Joshua Silverman Executive Chairman | AGrant or award Employee Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 50,000 | Apr 15, 2026 |
| Jan 16, 2026 | Chelsea Sierra Voss director | AGrant or award Common stock | +212,500 | $0.00 | $0 | 214,900 | Jan 30, 2026 |
| Jan 16, 2026 | Chelsea Sierra Voss director | AGrant or award Common stock | +25,000 | $0.00 | $0 | 239,900 | Jan 30, 2026 |
| Jan 16, 2026 | Chelsea Sierra Voss director | AGrant or award Employee Stock Option (Right to Buy)derivative | +212,500 | $0.00 | $0 | 212,500 | Jan 30, 2026 |
| Sep 4, 2025 | PharmaCyte Biotech, Inc. owner | POpen-market purchase Series H Convertible Preferred Stockderivative | +889,865 | - | - | 889,865 | Nov 18, 2025 |
| Nov 14, 2025 | PharmaCyte Biotech, Inc. owner | POpen-market purchase Warrantsderivative | +889,865 | - | - | 889,865 | Nov 18, 2025 |
| Nov 14, 2025 | Mitchell Glass Director, Chief Medical Off. | AGrant or award Common stock | +11,420 | $0.00 | $0 | 12,500 | Nov 17, 2025 |
| Nov 14, 2025 | Billy Joe White director | AGrant or award Common stock | +22,839 | $0.00 | $0 | 25,024 | Nov 17, 2025 |
| Nov 14, 2025 | Bruce Bernstein director | AGrant or award Common stock | +25,000 | $0.00 | $0 | 25,000 | Nov 14, 2025 |
| Nov 14, 2025 | Joshua Silverman Executive Chairman | AGrant or award Common stock | +91,356 | $0.00 | $0 | 100,029 | Nov 14, 2025 |
| Nov 14, 2025 | Gary M Rauch other | AGrant or award Common stock | +11,420 | $0.00 | $0 | 12,500 | Nov 14, 2025 |
| Nov 14, 2025 | Stephen Friscia director | AGrant or award Common stock | +22,839 | $0.00 | $0 | 25,000 | Nov 14, 2025 |
| Oct 3, 2025 | Stephen Friscia director | AGrant or award Common stock | +2,161 | $0.00 | $0 | 2,161 | Oct 6, 2025 |
| Oct 3, 2025 | Mitchell Glass Director, Chief Medical Off. | AGrant or award Common stock | +1,080 | $0.00 | $0 | 1,080 | Oct 6, 2025 |
| Oct 3, 2025 | Gary M Rauch other | AGrant or award Common stock | +1,080 | $0.00 | $0 | 1,080 | Oct 6, 2025 |
| Oct 3, 2025 | Joshua Silverman Executive Chairman | AGrant or award Common stock | +8,644 | $0.00 | $0 | 8,673 | Oct 6, 2025 |
| Oct 3, 2025 | Billy Joe White director | AGrant or award Common stock | +2,161 | $0.00 | $0 | 2,185 | Oct 6, 2025 |
| Apr 17, 2025 | Mitchell Glass President, CMO | AGrant or award Employee Stock Option (Right to Buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Apr 18, 2025 |
| Apr 17, 2025 | Gary M Rauch other | AGrant or award Employee Stock Option (Right to Buy)derivative | +75,000 | $0.00 | $0 | 75,000 | Apr 18, 2025 |
| Apr 17, 2025 | Ian Rhodes Interim CFO | AGrant or award Employee Stock Option (Right to Buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Apr 18, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Bruce Bernsteindirector
- Stephen Frisciadirector
- Mitchell GlassChief Medical Officer
- PharmaCyte Biotech, Inc.owner
- Gary M Rauchother
- Ian RhodesInterim CFO
- Joshua SilvermanExecutive Chairman
- Chelsea Sierra Vossdirector
- Billy Joe Whitecfo, officer, director
Questions about QCLS
Answered from the filings on this page, as of the latest one.
Are insiders buying QCLS?
No. In the last 90 days no insider at Q/C TECHNOLOGIES, INC. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade QCLS on the open market?
Chelsea Sierra Voss (director) bought $5,522 of QCLS on Mar 30, 2026 and filed the Form 4 on May 14, 2026. InsiderTell scored 15 (weak).
How many insiders file Form 4 at Q/C TECHNOLOGIES, INC.?
9 people have filed a Form 4 at Q/C TECHNOLOGIES, INC., among them Bruce Bernstein (director), Stephen Friscia (director), Mitchell Glass (Chief Medical Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.